Now Reading
Study of noninvasive retinal imaging device presented at Alzheimer’s conference

Study of noninvasive retinal imaging device presented at Alzheimer’s conference

Healthy brain (bottom) versus brain of a donor with Alzheimer's disease. Notable is the "shrink" that has occurred in Alzheimer's disease; the brain was decreased in size. (Photo credit: Wikipedia)

Healthy brain (bottom) versus brain of a donor with Alzheimer's disease. Notable is the "shrink" that has occurred in Alzheimer's disease; the brain was decreased in size. (Photo credit: Wikipedia)

Preliminary results show the device, created at Cedars-Sinai and developed by NeuroVision Imaging, may provide highly predictive early detection of changes associated with Alzheimer’s disease

A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer’s disease, according to preliminary results from investigators conducting a clinical trial in Australia.

The researchers will present their findings July 15 in an oral presentation at the Alzheimer’s Association International Conference 2014 in Copenhagen, Denmark. They also were invited by conference organizers to participate in a “breaking news” news conference beginning at 7:30 a.m. Sunday, July 13 in Copenhagen, 1:30 a.m. EDT.

“In preliminary results in 40 patients, the test could differentiate between Alzheimer’s disease and non-Alzheimer’s disease with 100 percent sensitivity and 80.6 percent specificity, meaning that all people with the disease tested positive and most of the people without the disease tested negative. The optical imaging exam appears to detect changes that occur 15-20 years before clinical diagnosis. It’s a practical exam that could allow testing of new therapies at an earlier stage, increasing our chances of altering the course of Alzheimer’s disease,” said Shaun Frost, a biomedical scientist and the study manager at the Commonwealth Scientific and Industrial Research Organisation. CSIRO is Australia’s national science agency.

Read more . . .

 

The Latest on: Alzheimer’s testing

[google_news title=”” keyword=”Alzheimer’s testing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]

via Google News

 

See Also
The newly developed antibody 6H4 fragments (Fabs) specific to A? oligomers, encapsulated in the polymeric nanomicelles (PMs), were peripherally administrated to AD model mouse for 10 weeks. In mice that were administered anti-A?O 6H4 Fabs in the PMs, various toxic A? species (A? oligomers, A?42s, N3pE A?s, A?s with toxic conformer) and the presence of A? plaques with dense cores in the brain were significantly reduced. Additionally, suppression of the progression of pathological processes of AD was supported by the prevention of cognitive-behavioral decline in the spatial memory tests. CREDIT Department of Neurology and Neurological Science, TMDU
The Latest on: Alzheimer’s testing

via  Bing News

 

 

What's Your Reaction?
Don't Like it!
0
I Like it!
0
Scroll To Top